• Vitronectin (VN) is produced by smooth muscle cells (SMCs) and promotes neointima formation.
Introduction
Vitronectin (VN) is an approximately 75-kDa acutephase-reactant plasma protein that is synthesized predominantly in the liver [1] . VN binds plasminogen activator inhibitor (PAI)-1, a serpin superfamily member that is the primary inhibitor of tissue-type plasminogen activator and urokinase plasminogen activator (u-PA) [2] , which stabilizes PAI-1 in its active conformation and inhibits fibrinolysis [3, 4] . In addition to plasma, VN is present in the extracellular matrix (ECM) of blood vessel walls and many other tissues, where it regulates cell adhesion and proteolysis through binding interactions with cell surface receptors and protease inhibitors, respectively [1] . VN also binds to structural proteins in the ECM, including collagen and elastin [5, 6] . Vascular smooth muscle cells (SMCs) express VN [7] . Under pathologic conditions, vascular wall expression of VN increases significantly, promoting intimal hyperplasia and vascular inflammation [8] . Vascular VN expression has also been implicated in the pathogenesis of atherosclerosis [9] [10] [11] . Similarly to VN expression, PAI-1 expression in the blood vessel wall increases in diseases characterized by vascular intimal hyperplasia, including diabetes mellitus and atherosclerosis [12, 13] . The binding interaction between VN and PAI-1 not only stabilizes PAI-1, but also regulates VN function, as PAI-1 competitively blocks binding of VN to a V b 3 integrin and the u-PA receptor (u-PAR), which are expressed by SMCs, producing an antimigratory effect [14] [15] [16] . PAI-1 also induces VN multimerization [17] .
Given the important vascular functions of VN, regulation of VN expression in the walls of blood vessels is likely to have pathophysiologic significance. Inflammatory signaling pathways have been shown to increase VN expression [18] . However, the control of vascular VN expression remains poorly understood. In a previous study, we demonstrated that the stoichiometric relationship between VN and PAI-1 in the ECM plays a key role in determining the effects of PAI-1 on SMC migration [19] . Given that PAI-1 and VN regulate each other's functions, SMCs express both VN and PAI-1 [7, 20] , and PAI-1/VN stoichiometry has physiologic significance, we hypothesized that PAI-1 regulates VN expression by SMCs, and controls vascular VN expression in vivo. We tested our hypothesis by analyzing the effects of genetic alterations in PAI-1 expression, recombinant PAI-1 proteins and a pharmacologic PAI-1 inhibitor on expression of VN by SMCs grown in culture, and by analysis of vascular wall and plasma expression of VN in mice. Our results suggest that PAI-1 has a previously unrecognized role in regulating the expression and distribution of VN in the vasculature.
Materials and methods

Animals
C57BL/6J mice were from Jackson Laboratories (Bar Harbor, ME, USA). C57BL/6J-congenic PAI-1-deficient (Pai1 À/À ) mice were a gift from P. Carmeliet, University of Leuven, Leuven, Belgium [21] . C57BL/6J-congenic VN-deficient (Vn À/À ) mice and PAI-1-transgenic (Tg)
mice that overexpress PAI-1 under the control of the cytomegalovirus promoter were from D. Ginsburg, University of Michigan [22, 23] . Mice received standard chow. All animal care and experimental procedures were approved by the University of Missouri Animal Care and Use Committee.
Recombinant PAI-1s and PAI-1 inhibitor
Recombinant, active murine PAI-1 was from Molecular Innovations (Novi, MI, USA). Recombinant human PAI-1 mutants were a gift from D. Lawrence (University of Michigan), and were expressed and purified as described previously [24] . PAI-1 mutants were: (i) PAI-1- 14-1B  (PAI-1 N150H, K154T, Q319L, and M354I) , an active, stable mutant (half-life of > 140 h under physiologic conditions) that binds VN with normal affinity [25] ; (ii) PAI-1-AK (PAI-1 N150H, K154T, Q319L, M354I, R101A,  and Q123K) , an active, stable mutant with no detectable VN binding [26] ; and (iii) PAI-1-E (PAI-1 N150H, K154T, Q319L, M354I, and R76E), an active stable mutant with markedly reduced binding affinity for LDL receptor-related protein-1 (LRP1), but normal VN binding affinity [19] . PAI-039, a pharmacologic inhibitor of PAI-1, was from Pfizer (Cambridge, MA, USA) [27] .
Cell culture
SMCs were isolated from mouse aortas, and cell culture lines were established as described previously [28] . SMCs (2 9 10 5 ) were seeded in six-well cell culture plates in Dulbecco's modified Eagle's medium (DMEM)/F12 supplemented with 10% fetal bovine serum, and grown to 80% confluency; medium was then removed, and serum-free DMEM/F12 was added to the wells. Cells were treated with recombinant PAI-1, PAI-039 or a 2 -macroglobulin-trypsin complex for 4-24 h, after which cells were washed and harvested for analysis. Complexes of human a 2 -macroglobulin (Cat. No. 63013; SigmaAldrich, St Louis, MO, USA) and trypsin (Sangon Biotech, Shanghai, China) were prepared and treated with soybean trypsin inhibitor (Sangon Biotech) to inactive free trypsin, as described previously [29, 30] . In some experiments, SMCs were preincubated with a rabbit anti-LRP1 antibody (R2629, 100 lg mL À1 ; kindly provided D. Strickland, University of Maryland) prior to addition of PAI-1. R2629 does not cross-react with any other known LDL receptor family member [31] . 
In vivo analyses of VN expression
Adult male mice were anesthetized. Blood was collected, by cardiac puncture, into citrate anticoagulant, and plateletpoor plasma was prepared and frozen. The vasculature was perfused with saline. The common carotid arteries were excised, and total cellular RNA was extracted from one artery by the use of TRIzol, according to the manufacturer's instructions. Proteins were extracted from the other carotid artery by cutting it into small pieces, placing them in RIPA buffer, and grinding them with a hand-held tissue homogenizer. Homogenates were centrifuged at 16 000 9 g at 4 degree for 15 min, and supernatants were prepared by centrifugation for 10 minutes at 600 9 g and saved for western blot analysis. To study VN expression under pathologic conditions, a vein graft model of intimal hyperplasia was utilized, which involves transplant of a segment of the inferior vena cava from a donor mouse into the carotid artery of a recipient mouse [33] . Blood samples were collected from mice at 5 days, 4 weeks and 8 weeks after surgery, and citrated plasma was prepared and frozen. Vein grafts were harvested 4 weeks after surgery. Cross-sections (5 lm in thickness) were mounted on glass slides, deparaffinized, hydrated, incubated for 10 min in methanol containing 3% H 2 O 2 , and rinsed. VN immunostaining in vein grafts was performed with a rat anti-mouse VN mAb (MAB3875; R&D Systems, Minneapolis, MN, USA) and an HRP-conjugated broad-spectrum secondary antibody (Histomouse-MAX Kit; Invitrogen, Carlsbad, CA, USA). As a negative control, immunostaining was also performed by substituting non-immune rat IgG for anti-VN IgG. Identical, simultaneously performed immunostaining techniques (i.e. antibody dilutions, incubation, and wash times) were used for all samples.
Statistical analyses
All experiments were performed at least in triplicate, with results reported as mean AE standard error of the mean. Student's t-test or one-way ANOVA was used to compare experimental groups, as appropriate.
Results
VN gene expression and protein concentration are decreased in PAI-1-deficient SMCs. We used qRT-PCR to study VN gene expression in murine SMCs grown in culture. VN gene expression was markedly decreased in PAI-1-deficient SMCs as compared with wild-type (WT) controls (Fig. 1A) . Conversely, PAI-1 gene expression was not significantly altered in VN-deficient SMCs as compared with WT controls (Fig. 1B) . VN gene expression was significantly increased in PAI-1-Tg SMCs as compared with WT controls (Fig. 1A) . Western blot analysis of SMC lysates confirmed that the VN protein level was significantly reduced in PAI-1-deficient SMCs as compared with WT controls, whereas the difference in VN protein concentration in lysates prepared from PAI-1-Tg versus WT SMCs did not reach statistical significance (Fig. 1C) . Consistent with the gene expression data, PAI-1 protein content did not differ significantly between WT and VN-deficient SMCs (Fig. 1D) . Overall, these results suggested that genetic alterations in PAI-1 expression significantly alter VN expression in vascular SMCs. Silencing of PAI-1 gene expression decreases VN gene expression in SMCs. We treated murine SMCs grown in culture with PAI-1 siRNA. This intervention, which resulted in an approximately 50% reduction in PAI-1 gene expression and an approximately 70% reduction in PAI-1 protein concentration as compared with negative control siRNA ( Fig. 2A,C,D) , was accompanied by similar reductions in VN gene expression and protein level (Fig. 2B-C,  E) . These results suggested that a short-term reduction in PAI-1 expression decreases VN expression by SMCs.
Pharmacologic inhibition of PAI-1 decreases VN expression. Murine SMCs were grown in culture and allowed to achieve ⁓ 80% confluency. PAI-039 (25 lM), a highly specific PAI-1 inhibitor, or vehicle control was added, and cells were incubated for an additional 24 h, after which total cellular RNA was isolated and analyzed by qRT-PCR. PAI-039 significantly decreased VN gene expression without inhibiting PAI-1 gene expression (Fig. 3) , suggesting that PAI-1 antiprotease activity was required for stimulation of VN gene expression.
Recombinant PAI-1 stimulates SMC VN expression by binding to LRP1. Addition of recombinant PAI-1 to cell culture medium stimulated VN gene expression in WT mouse SMCs (Fig. 4A) . To study the mechanism underlying this effect, we treated PAI-1-deficient murine SMCs with recombinant human PAI-1 mutants. PAI-1-14-1B, a stable mutant with intact antiprotease and VN-binding functions, significantly stimulated VN expression (Fig. 4B) . PAI-1-AK, an active mutant deficient in VN-binding function, also significantly increased VN expression, producing an effect that was significantly greater than that of PAI-1-14-1B. However, PAI-1-E, an active mutant defective in binding to LRP1 and other LDL receptor family members, did not stimulate SMC VN expression. R2629, a specific anti-LRP1 antibody that does not recognize other LDL receptor family members [31] , completely blocked the capacity of PAI-1-14-1B to stimulate VN expression (Fig. 4C) . The capacity of another LRP1 ligand, a 2 -macroglobulin, to stimulate VN expression was studied by incubating SMCs with complexes composed of a 2 -macroglobulin and trypsin, which bind LRP1 and induce intracellular signaling [34, 35] . Unlike PAI-1, a 2 -macroglobulin-trypsin complex had no significant effect on VN expression by SMCs (Fig. 5) . Together, these results suggested that: (i) the stimulatory effect of extracellular PAI-1 on SMC VN expression is mediated by binding to LRP1; (ii) endogenous expression of PAI-1 is not required to stimulate SMC VN expression; and (iii) not all LRP1 ligands enhance VN expression by SMCs.
PAI-1 regulates VN expression in vivo. To examine the in vivo significance of our findings, we compared VN expression in blood vessels from WT mice, PAI-1-deficient mice, and PAI-1-Tg mice. There were significantly lower levels of VN mRNA and protein in carotid arteries of PAI-1-deficient mice than in those of WT controls, and significantly higher levels of VN mRNA and protein in carotid arteries of PAI-1-Tg mice than in those of WT controls (Fig. 6A,C) . qRT-PCR analysis confirmed that PAI-1 gene expression was increased in carotid arteries of PAI-1-Tg mice as compared with WT controls, and was absent in PAI-1-deficient mice (Fig. 6B) .
To examine the effects of PAI-1 on VN expression under a clinically relevant form of acute stress, we subjected mice to vein graft surgery, which involves interposition of a segment of vena cava harvested from a donor mouse into the transected carotid artery of a recipient mouse [33, 36] . Plasma VN levels in recipient WT mice 5 days after surgery were significantly higher than those in non-operated WT controls (Fig. 7) , consistent with the acute-phase regulation of VN expression [18] . At this early time point after surgery, there was no significant difference in plasma VN level between WT mice and PAI-1-deficient mice. However, at 4 weeks after surgery, the plasma VN level was significantly higher in WT mice than in PAI-1-deficient mice. At 8 weeks after surgery, the plasma VN level was similar to that found in non-operated controls, and did not differ significantly between WT mice and PAI-1-deficient mice.
Immunohistochemistry was used to assess VN expression and localization in vein grafts retrieved 4 weeks after surgery. In WT mice, VN was localized in the interface of the intimal and medial vascular layers (Fig. 8A) . In contrast, the VN protein level in neointimal lesions was significantly lower than that in PAI-1-deficient mice (Fig. 8C) . To further explore the role of PAI-1 in regulating VN expression in vein grafts, we performed surgeries involving interposition of PAI-1-deficient vein segments into the carotid arteries of WT mice to generate Pai1 À/À donor /WT recipient mice. VN expression in vein grafts harvested 4 weeks after surgery was significantly reduced in Pai1 these in vivo results support an important role of PAI-1 in regulating VN expression in plasma and the vascular wall.
Discussion
VN expression increases in blood vessels after injury, which supports neointimal growth [8] . However, the factors that regulate vascular VN expression are poorly defined. In this study, we performed a series of in vitro and in vivo experiments to study the effects of PAI-1 on the regulation of VN expression in the vasculature. Our in vitro experiments focused on SMCs, which express PAI-1 and VN, and play key roles in normal vascular function and pathologic vascular remodeling. Our results demonstrate that PAI-1 regulates VN gene expression. To our knowledge, a role of PAI-1 in controlling gene expression has not been reported previously. However, there is a precedent for regulation of gene expression by a serpin family member, as antithrombin III has been shown to significantly downregulate the expression of host cell signal transduction factors, most notably bone morphogenetic protein 2 [37] . PAI-1 and VN are dependent on each other for their function. VN stabilizes PAI-1 in an active conformation [3, 4] . PAI-1 controls the cell adhesion function of VN by competitively blocking its binding to a V b 3 integrin and u-PAR [16] . Furthermore, the stoichiometric relationship between PAI-1 and VN plays an important role in controlling SMC migration [19] . Hence, the existence of systems for coordinated expression of VN and PAI-1, including an autocrine loop by which PAI-1 released by SMCs regulates their production of VN, would not be unexpected. The regulation of VN expression by PAI-1 has the potential to have considerable significance in vascular disorders, including chronic diseases characterized by overexpression of PAI-1, such as diabetes mellitus and atherosclerosis [12, 13] . In addition, short-term increases in PAI-1 levels in the vasculature, as occur with thrombosis and balloon angioplasty [38, 39] , may contribute to the surge in VN expression after vascular injury that contributes to neointima formation [8] .
Our data obtained with recombinant PAI-1 mutants and anti-LRP1 antibody suggest that binding of PAI-1 to LRP1 is required to enhance VN expression. Binding of PAI-1 to LRP1 activates intracellular signaling pathways that regulate gene expression, including JAK-STAT1 signaling [32, 40] . It is of note that we observed significantly greater stimulation of VN gene expression by PAI-1-AK, which does not bind VN, than by PAI-1-14-1B; this is most likely explained by the recognized capacity of VN to downregulate the binding of PAI-1 to LRP1 [41] . The capacity of PAI-1 to signal via LRP1 is complex, and can involve binding of PAI-1 to u-PA, the latter of which may be bound to its receptor, u-PAR [42] . Binding of PAI-1 to u-PA induces a conformational change in PAI-1 that exposes its binding site for LRP1 [43] . u-PAR can bind directly to LRP1 and to integrins, which can trigger intracellular signaling [44, 45] . The macro-complex of LRP1, PAI-1, u-PA, u-PAR and integrin undergoes endocytosis, with targeting of PAI-1 and u-PA to endosomes for degradation and recycling of LRP1, u-PAR and integrin to the cell membrane. In addition to controlling cell adhesion and migration, this LRP1-mediated endocytic process is accompanied by activation of intracellular signaling pathways that regulate cell migration and other functions [42] . Although we did not measure u-PA in our experiments, u-PA is expressed by SMCs [46] , and was probably present in our cell culture studies. Our experiments did not resolve whether PAI-1 must be internalized to stimulate VN expression, and nor did they determine whether PAI-1 acts via an intracellular mechanism in upregulating VN expression. However, our experiments involving addition of recombinant PAI-1 to PAI-1-deficient SMCs demonstrate that cell synthesis of PAI-1 is not required for PAI-1 to stimulate VN expression, and support an autocrine mechanism by which secreted PAI-1 binds LRP1 and activates an outside-in signaling pathway that upregulates VN gene expression. Additional studies will be needed to clarify the precise molecular signaling events that mediate the effects of PAI-1 on VN expression. It will also be of interest to study the effects of the many other ligands of LRP1 on VN expression. Our finding that a 2 -macroglobulin, which binds to and is endocytosed by LRP1 [34] , does not stimulate SMC VN expression suggests that there are significant differences in VN expression in response to different LRP1 ligands.
There is growing interest in the potential of pharmacologic PAI-1 inhibitors to treat and prevent vascular diseases [47, 48] . We have shown that pharmacologic targeting of PAI-1 with PAI-039, a highly specific PAI-1 inhibitor, decreases VN expression, suggesting that downregulation of VN expression may be an additional Fig. 7 . Effect of plasminogen activator inhibitor (PAI)-1 genotype on the plasma vitronectin (VN) level after surgery. The VN level in plasma was measured by ELISA in non-operated mice (control) and in mice after vein graft surgery, at the indicated time points. The numbers of mice in the different groups are shown. All data shown are from mice that received vein grafts from donor mice with the same genotype (that is, wild-type [WT] vein segments were transplanted into WT mice, and PAI-1-deficient vein segments were transmechanism by which pharmacologic inhibition of PAI-1 decreases SMC migration and adverse vascular remodeling [32] .
Our studies involving assessment of VN expression in arteries and vein grafts confirm that increases and decreases in PAI-1 expression produce commensurate changes in vascular VN expression in vivo. Furthermore, our experiments involving a vein graft model provide important insights into the source of the PAI-1 that regulates neointimal VN expression. In a previous study, we showed that the plasma PAI-1 level does not differ significantly between mice that receive WT vein grafts and those that receive PAI-1-deficient vein grafts [36] . Therefore, the significant reduction in VN content in vein grafts from Pai1 VN is an acute-phase reactant plasma protein whose level increases significantly in response to stress [18] . In our murine surgical model, we found that the plasma VN level increased significantly on the fifth postoperative day. However, at this early time point, when multiple pathways that stimulate expression of VN and other acutephase reactant proteins would be expected to be strongly activated, there was no discernable effect of PAI-1 genotype on the plasma VN level. At 4 weeks after surgery, the plasma VN level was significantly lower in PAI-1-deficient mice than in WT controls, although this difference between genotypes dissipated by 8 weeks after surgery, at which time the mice would be expected to have completely recovered from surgery. Consistent with our late postoperative data, there was no significant difference in the plasma VN level between WT and PAI-1-deficient mice under basal conditions. Overall, these results suggest that PAI-1 can modulate the plasma VN level under stress conditions, but does not exert a major effect in comparison with other inflammatory mediators, such as interleukin-6 [49] . Interestingly, Ekmekci et al. found a positive correlation between plasma PAI-1 activity and VN level in patients with symptomatic carotid artery disease [50] , consistent with our cell culture and in vivo data, and supporting the hypothesis that PAI-1 regulates VN expression.
In summary, we have shown that PAI-1 plays a previously unrecognized role in regulating the expression of VN by SMCs and controlling vascular VN expression in vivo. Therefore, downstream effects of PAI-1 on the vascular expression of VN may represent another important mechanism by which PAI-1 regulates SMC migration and vascular remodeling. The stimulatory effect of PAI-1 on SMC VN expression is LRP1-dependent. Together, these findings demonstrate that VN depends on PAI-1 for its function, not only through direct binding interactions, but also via regulation of VN gene expression by PAI-1. 
